What 6 Analyst Ratings Have To Say About EyePoint Pharmaceuticals
Portfolio Pulse from Benzinga Insights
EyePoint Pharmaceuticals (NASDAQ:EYPT) has received six analyst ratings in the last quarter, with five being bullish, one somewhat bullish, and none being bearish or indifferent. The average price target is $31.33, representing a significant upside from the current price of $8.0. However, this average price target is a 4.1% decrease from the previous average price target of $32.67.
June 28, 2023 | 3:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
EyePoint Pharmaceuticals has received positive analyst ratings, which could potentially drive its stock price up in the short term.
Analyst ratings often influence investor sentiment and can impact a stock's price. In this case, EyePoint Pharmaceuticals has received predominantly positive ratings, which could make the stock more attractive to investors and potentially drive its price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100